Previous Close | 2.4640 |
Open | 1.4330 |
Bid | 1.4660 x N/A |
Ask | 1.6740 x N/A |
Day's Range | 1.4330 - 1.4330 |
52 Week Range | 1.4330 - 1.4330 |
Volume | |
Avg. Volume | N/A |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Nemaura Medical Inc (NASDAQ: NMRD) has announced initial results from patient studies of its metabolic health program Miboko with the National Health Service (NHS) in the U.K. The initial pilot program recruited 30 individuals classified as obese according to their BMI. The first cohort of 10 patients enrolled in the program for over 12 weeks. Results from this cohort indicate that these individuals achieved an average weight loss of 3.7 pounds and an average BMI improvement of 0.6 after 10 week
Nemaura Medical, Inc. (NMRD) delivered earnings and revenue surprises of 0% and 75.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
In this article, we will discuss the top 10 stock picks of Julian Robertson’s Tiger Management. If you want to skip our discussion on Robertson’s illustrious career and legacy, go directly to the 5 Stock Picks of Julian Robertson’s Tiger Management. Julian Robertson was a pioneer in the hedge fund industry as he co-founded one […]